New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:35 EDTILMN, WXWuXi PharmaTech purchases Illumina HiSeq X Ten Sequencing System
Illumina (LMN) and WuXi PharmaTech (WX) announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. This new investment will enable WuXi’s clinical genomic services to expand from the current target panel, exome, and transcriptome scale sequencing to population genome scale sequencing. It puts the world’s most advanced gene sequencing capability in the hands of the leading pharmaceutical R&D services company in the Asia Pacific region. The WuXi Genome Center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. In addition to offering sequencing services, WuXi’s genomics lab also provides assay development, validation, and testing services.
News For WX;ILMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 18, 2015
08:33 EDTILMNTrovagene appoints Matthew Posard as Chief Commercial Officer
Subscribe for More Information
March 16, 2015
09:45 EDTWXWuXi PharmaTech management to meet with
Subscribe for More Information
05:40 EDTILMNIllumina files patent infringement suit in UK regarding NIPT patents
Illumina (ILMN) announced that it and its wholly-owned subsidiary, Verinata Health have filed a patent infringement suit against Premaitha Health in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief. The patents asserted are European Patent 0 994 963 B2 and European Patent 1 981 995 B1, which are exclusively licensed to Illumina from Sequenom (SQNM), and The Board of Trustees of Leland Stanford Junior University, respectively. Stanford is joined in the suit as a necessary party because it is the registered owner of the European Patent 1 981 995 B1. The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing. The suit accuses Premaitha’s IONA Test of infringement, including its use of next-generation sequencing to analyze cell-free fetal DNA from a sample of maternal blood.
March 13, 2015
09:49 EDTILMNUBS life science tools/diagnostics analyst has analyst/industry conference call
Subscribe for More Information
March 12, 2015
10:01 EDTWXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:09 EDTWXWuXi PharmaTech downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
08:23 EDTWXWuXi PharmaTech to build new manufacturing facility for cell therapy products
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use